Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists (ROAR)
Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists - a Study in Opioid naïve Individuals and Chronic Opioid Users Under Real-life Conditions
Sponsor: Leiden University Medical Center
This PHASE1 trial investigates Chronic Opioid Use and Opioid Induced Respiratory Depression and is currently actively recruiting participants. Leiden University Medical Center leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
8 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE1
-
Feb 2025 — Jun 2025 [monthly]
Recruiting PHASE1
Status: Completed → Recruiting
-
Nov 2024 — Feb 2025 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Feb 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Leiden University Medical Center
- U.S. Food and Drug Administration (FDA)
For direct contact, visit the study record on ClinicalTrials.gov .